Association for Molecular Pathology v. Myriad Genetics, Inc.: The Ultimate Guide to Gene Patenting

LEGAL DISCLAIMER: This article provides general, informational content for educational purposes only. It is not a substitute for professional legal advice from a qualified attorney. Always consult with a lawyer for guidance on your specific legal situation.

Imagine a prospector discovers a new, incredibly valuable mineral—let's call it “Healium”—buried deep in a public mountain range. This mineral has the unique property of curing a specific disease. The prospector painstakingly digs it up, cleans it, and presents it to the world. Should they be allowed to get a patent not just on their method of extraction, but on Healium itself? Could they prevent anyone else from digging up Healium, even on the other side of the mountain? This is the exact dilemma the `supreme_court_of_the_united_states` faced in Association for Molecular Pathology v. Myriad Genetics, Inc., but instead of a mineral, the “discovery” was a segment of your own DNA. The case asked a monumental question: Can a private company own a piece of the human genome? The Court's answer reshaped the landscape of medicine, patient rights, and scientific innovation forever, directly impacting the cost and availability of life-saving genetic tests for diseases like breast and ovarian cancer.

• Key Takeaways At-a-Glance:
  • You Cannot Patent Nature: The Supreme Court's landmark ruling in Association for Molecular Pathology v. Myriad Genetics, Inc. established that naturally occurring human genes, even when isolated from the body, are “products of nature” and cannot be patented. patent_law.
  • Invention, Not Discovery, is Key: The decision affirmed a core principle of intellectual_property: a patent is a reward for invention, not for discovery. Myriad found the BRCA genes; they did not invent them. product_of_nature_doctrine.
  • Synthetic DNA is Different: The Court distinguished between natural DNA and synthetic, lab-created DNA called cDNA. It held that cDNA is patent-eligible because it is not found in nature and is the result of human ingenuity.
  • Immediate Patient Impact: This ruling immediately broke Myriad's monopoly, allowing other labs to offer BRCA gene testing. This sparked competition, drastically lowered costs from over $3,000 to a few hundred dollars, and increased patient access to critical health information. genetic_testing.

In the 1990s, scientists made a monumental breakthrough in the fight against cancer. Researchers at the University of Utah, funded in part by Myriad Genetics, identified the exact location and sequence of two specific human genes: BRCA1 and BRCA2. Mutations on these genes were found to be strongly linked to a dramatically increased risk of hereditary breast and ovarian cancer. This was a life-changing discovery. With this knowledge, individuals could be tested to see if they carried these mutations, allowing them to make proactive, life-saving decisions about their health. Myriad Genetics, a young biotech company, quickly capitalized on this discovery. They obtained a series of patents that gave them a complete monopoly in the United States over the BRCA1 and BRCA2 genes themselves, as well as any method of testing for them. For nearly two decades, if you wanted to be tested for these critical mutations, you had one option: Myriad. This monopoly had profound consequences:

• Exorbitant Costs: With no competition, Myriad charged over $3,000 for its test, placing it out of reach for many uninsured or underinsured individuals.
• No Second Opinions: If a patient received an ambiguous result or wanted to confirm a finding, they could not go to another lab. Myriad controlled all testing and all the data.
• Stifled Research: The patents prevented other scientists and researchers from freely studying the BRCA genes, potentially slowing down the development of new tests, therapies, and our overall understanding of hereditary cancer.

This situation gained widespread public attention when actress Angelina Jolie wrote a New York Times op-ed in 2013, revealing she had undergone a preventive double mastectomy after a Myriad test showed she carried the BRCA1 mutation. While her story raised crucial awareness, it also highlighted the high cost and limited access that defined the era of Myriad's patent monopoly.

The scientific and patient communities grew increasingly frustrated. They argued that a company should not be able to own a fundamental piece of the human body. In 2009, the `american_civil_liberties_union` (ACLU) and the Public Patent Foundation filed a lawsuit on behalf of the `association_for_molecular_pathology` (AMP), researchers, genetic counselors, and patients. The case began a long and winding journey through the federal court system:

1. District Court (2010): The U.S. District Court for the Southern District of New York sided with the challengers, ruling that Myriad's patents on the isolated genes were invalid. The judge reasoned that the DNA was a product of nature.
2. Federal Circuit (2011): Myriad appealed to the U.S. Court of Appeals for the Federal Circuit, the specialized court that handles all `patent_law` appeals. In a split decision, the Federal Circuit reversed the lower court, finding that the act of “isolating” the DNA from the body made it a distinct, human-made invention and therefore patentable.
3. Remand from the Supreme Court: The case was appealed to the Supreme Court. However, the Court first decided another major patent case, `mayo_collaborative_services_v_prometheus_laboratories_inc`, which narrowed the scope of what could be patented. The Supreme Court then vacated the Federal Circuit's Myriad decision and sent it back to them, essentially telling them to “re-do your homework in light of the *Mayo* ruling.”
4. Federal Circuit, Round Two (2012): In a surprising move, the Federal Circuit largely stuck to its original conclusion, once again ruling in favor of Myriad. This set up a direct conflict between the patent court's interpretation and the principles laid out by the Supreme Court in *Mayo*.

With the lower courts in disagreement, the stage was set for a final, definitive showdown at the `supreme_court_of_the_united_states`.

The entire case boiled down to a single section of U.S. patent law, 35_usc_101, which states that anyone who “invents or discovers any new and useful process, machine, manufacture, or composition of matter” may obtain a patent. However, the courts have long established crucial exceptions to this rule. You cannot patent:

1. **Laws of Nature** (e.g., E=mc², gravity)
2. **Natural Phenomena** (e.g., a new mineral found in the earth, a plant)
3. **Abstract Ideas** (e.g., a mathematical algorithm)

The challengers argued that a human gene, even when removed from the body, is a classic “natural phenomenon.” It contains the same exact genetic information as it does inside our cells. Myriad, on the other hand, argued that by isolating the gene—a complex biochemical process—they had created a new “composition of matter” that was distinct from its natural state and therefore a patentable invention. The Supreme Court had to decide: is isolating a gene an act of discovery or an act of invention?

On June 13, 2013, the Supreme Court issued a unanimous (9-0) decision that fundamentally altered the landscape of biotechnology. In an opinion written by Justice Clarence Thomas, the Court delivered a nuanced but powerful verdict: naturally occurring DNA is not patentable, but synthetic DNA can be. The decision was a major victory for the petitioners and a blow to Myriad Genetics, effectively invalidating the most critical claims of its patents.

The Court's reasoning was elegant in its simplicity. It carefully distinguished between two types of DNA at the heart of the case: isolated genomic DNA (gDNA) and complementary DNA (cDNA). Understanding this distinction is key to understanding the ruling.

Myriad's primary argument was that its scientists had invented something new by snipping the BRCA genes out of the vastly longer strand of human DNA. The Court flatly rejected this. Justice Thomas wrote that Myriad “did not create anything. To be sure, it found an important and useful gene, but separating that gene from its surrounding genetic material is not an act of invention.” He used a powerful analogy: a person who discovers a new, valuable plant in the wild cannot patent the plant itself, even if they were the first to recognize its useful properties. Likewise, “the discovery of the precise location and sequence of the BRCA1 and BRCA2 genes” was a groundbreaking scientific achievement, but it was a discovery, not an invention. The Court held that the genetic information encoded in the BRCA genes was the same inside the body as it was in Myriad's isolated sample. The act of isolation did not change the gene's fundamental quality as a product of nature. This officially closed the door on patenting genes that are simply taken from a natural source.

The Court then turned to cDNA. This is where the science gets a little more complex, but the legal principle is clear.

• In nature, genes (gDNA) contain both coding regions (exons) and non-coding regions (introns).
• When our cells “read” a gene to make a protein, they create a messenger RNA (mRNA) molecule that copies only the exons, cutting out the introns.
• In a lab, scientists can use that mRNA molecule as a template to create a DNA strand. This synthetic, lab-created DNA is called complementary DNA (cDNA).

Because cDNA is created by stitching together only the exons, its sequence is different from the gene as it exists in our bodies. It is an edited, intron-free version. The Supreme Court seized on this difference. Justice Thomas wrote that cDNA is “not a 'product of nature,'“ and is therefore patent-eligible under 35_usc_101 because the lab technician “unquestionably creates something new” when making it. To use an analogy, if a natural gene is a full-length novel with chapter introductions and appendices (introns), cDNA is like a “Reader's Digest” version containing only the core story chapters (exons). It's derived from the original, but it's a new, human-made creation.

The Myriad ruling created a clear dividing line for biotech companies across the nation. It didn't destroy all biotech patents, but it forced a major shift in strategy, moving away from patenting discoveries and toward patenting genuine applications and inventions.

The *Myriad* decision was not an abstract legal debate; it had immediate, tangible consequences for millions of Americans, transforming the landscape of personal medicine.

The moment the Supreme Court's decision was announced, the world of genetic testing changed.

1. Step 1: The Monopoly Shatters: Within hours of the ruling, multiple companies, including Quest Diagnostics and LabCorp, announced they would begin offering their own BRCA gene tests. Myriad's two-decade monopoly was over.
2. Step 2: Prices Plummet: Basic economics took over. With competition flooding the market, the price for BRCA testing collapsed. The test that had cost patients over $3,000 soon became available for under $1,000, and eventually, as low as a few hundred dollars. This made screening accessible to a vastly larger portion of the population.
3. Step 3: Innovation Explodes: The most profound impact was on innovation. Freed from the fear of patent infringement, companies were no longer limited to testing one or two genes. They began developing “multi-gene panels” that could test for dozens, or even hundreds, of cancer-related gene mutations at once, often for less than the cost of Myriad's original two-gene test. This gave doctors and patients a much more comprehensive view of genetic risk.
4. Step 4: Patients are Empowered: The decision shifted power to patients. They now had choices, could seek second opinions, and could access their own genetic data for use in broader research. The ruling helped accelerate the era of personalized medicine, where healthcare decisions are tailored to an individual's unique genetic makeup.

While you won't file legal forms, understanding the documents you receive after the *Myriad* decision is crucial.

• Informed Consent Form: Before any genetic test, you will sign this document. It explains the risks, benefits, and limitations of the test. Read this carefully. It will detail who owns the physical sample (usually the lab) and how your anonymized data might be used for research.
• Genetic Test Report: This is your results document. Thanks to the competition fostered by *Myriad*, these reports are more detailed than ever. They will typically identify:
  • Variants Detected: Any specific mutations found (e.g., a “pathogenic variant” in BRCA1).
  • Variant Classification: Whether the variant is “pathogenic” (harmful), “benign” (harmless), or a “variant of unknown significance” (VUS). The ability for multiple labs to study genes has helped clarify many VUS results over time.
  • Interpretation and Recommendations: A summary of what the results mean for your health risks and recommendations for consulting with a genetic counselor.

The *Myriad* ruling didn't happen in a vacuum. It was the culmination of decades of legal precedent grappling with the line between nature and technology.

• The Backstory: Ananda Chakrabarty, a genetic engineer for General Electric, developed a bacterium capable of breaking down crude oil, which he hoped to use in cleaning up oil spills. The `us_patent_and_trademark_office` (USPTO) rejected his patent application on the grounds that living things were not patentable subject matter.
• The Legal Question: Can a living, man-made microorganism be patented?
• The Holding: In a 5-4 decision, the Supreme Court said yes. Chief Justice Burger famously wrote that patentable subject matter includes “anything under the sun that is made by man.” Because Chakrabarty's bacterium was modified in a way that did not occur naturally, it was a human invention.
• Impact on Myriad: *Chakrabarty* opened the door for the entire biotechnology industry and was the legal foundation Myriad relied on. Myriad argued that, like the bacterium, their isolated DNA was a man-made product. The *Myriad* court had to explain why isolated DNA was different, clarifying that *Chakrabarty* required a truly new creation, not just the purification of a natural one.

• The Backstory: Prometheus patented a method for doctors treating autoimmune diseases. The patents covered the steps of administering a drug and then measuring the level of a metabolite in the patient's blood to see if the dosage was correct.
• The Legal Question: Can a patent be granted for a process that does little more than describe a natural law or correlation?
• The Holding: The Supreme Court unanimously said no. Justice Breyer wrote that the process was not a patentable invention because it merely described the natural relationship between the drug's concentration and its therapeutic effect. The steps of “administering” and “measuring” were considered routine. To be patentable, a process must contain an “inventive concept” beyond the natural law itself.
• Impact on Myriad: Decided just one year before *Myriad*, the *Mayo* decision was a crucial turning point. It signaled the Court's growing concern that the patent system was overreaching into the domain of natural principles. The *Myriad* court applied the *Mayo* framework directly, viewing the genetic code as a fundamental law of nature and concluding that merely “reading” it was not a patentable act of invention.

The *Myriad* decision settled the question of patenting natural genes, but it opened up a new Pandora's box of legal challenges at the cutting edge of biotechnology.

The new frontier is not about reading genes, but about writing and editing them. Technologies like `crispr` (Clustered Regularly Interspaced Short Palindromic Repeats) have created a gene-editing tool of unprecedented power and precision. This has led to fierce, multi-billion dollar patent battles, most notably between the University of California and the Broad Institute. The legal questions are different now:

• Can you patent the CRISPR-Cas9 system itself as a tool?
• Can you patent a method of using CRISPR to treat a specific disease?
• Can you patent a specific guide RNA molecule that directs the CRISPR system to a particular gene?

These patents are generally considered stronger than Myriad's were because they cover a human-made technology—a method and a tool—not the underlying gene being edited. However, the courts are still working to define the precise boundaries, applying the principles from *Mayo* and *Myriad* to this revolutionary new field.

The next wave of legal challenges will likely involve the intersection of genetics, big data, and artificial intelligence. Companies are now developing complex algorithms that can analyze a person's entire genome, along with their health records and lifestyle data, to predict their risk for hundreds of diseases. This raises new questions:

• Is an AI diagnostic algorithm an unpatentable “abstract idea,” like the one in *Mayo*?
• Or is it a patentable invention, a new “machine” for analyzing health data?
• Who owns the insights generated when an AI analyzes the genetic data of millions of people?

As technology continues to evolve, the courts will be forced to repeatedly revisit the fundamental question at the heart of the *Myriad* case: where is the line between discovering a truth about our natural world and inventing a tool that benefits humanity? The legacy of *Myriad* is its powerful reminder that the basic building blocks of nature—including our own genes—are the shared inheritance of all people, and cannot be owned.

• 35_usc_101: The section of U.S. patent law that defines what subject matter is eligible for a patent.
• aclu: The American Civil Liberties Union, a non-profit organization that was a lead plaintiff in the case against Myriad.
• brca1_brca2: Human genes that, when mutated, are associated with a high risk of hereditary breast and ovarian cancer.
• cdna: Complementary DNA, a synthetic, lab-created form of DNA that contains only the protein-coding parts of a gene (exons).
• crispr: A revolutionary gene-editing technology that allows scientists to make precise changes to DNA sequences.
• dna: Deoxyribonucleic acid, the molecule that carries the genetic instructions for the development and functioning of all known organisms.
• gene: A specific sequence of nucleotides in DNA that is located on a chromosome and is the basic unit of heredity.
• genetic_testing: The sequencing of human DNA to discover genetic differences, anomalies, or mutations.
• intellectual_property: A category of property that includes intangible creations of the human intellect, such as patents, copyrights, and trademarks.
• isolated_dna: DNA that has been removed from its natural cellular environment and separated from other genetic material.
• patent: A government authority or license conferring a right or title for a set period, especially the sole right to exclude others from making, using, or selling an invention.
• patent_law: The body of law that governs the creation, protection, and enforcement of patents.
• product_of_nature_doctrine: A legal principle stating that things that exist in nature are not patentable, even if newly discovered.
• supreme_court_of_the_united_states: The highest federal court in the United States, which made the final ruling in this case.
• us_patent_and_trademark_office: The federal agency responsible for issuing patents and registering trademarks.

• patent_law
• intellectual_property
• product_of_nature_doctrine
• mayo_collaborative_services_v_prometheus_laboratories_inc
• diamond_v_chakrabarty
• genetic_testing
• supreme_court_of_the_united_states